GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jun 23, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jun 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-repurchase
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on June 23, 2025, that it has purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — The company making the share repurchase.
- Merrill Lynch International (company) — The corporate stockbroker acting on behalf of GSK plc.
FAQ
What is the specific number of GSK plc ordinary shares purchased?
The filing states that a 'number' of shares were purchased but does not specify the exact quantity.
What is the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the transaction.
On what date did GSK plc announce this transaction?
GSK plc announced the transaction on June 23, 2025.
Who is acting as GSK plc's corporate stockbroker for this transaction?
Merrill Lynch International is acting as GSK plc's corporate stockbroker.
What is the par value of GSK plc's ordinary shares?
The ordinary shares have a par value of 31¼ pence each.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 23, 2025 regarding GSK plc (GLAXF).